scholarly journals Gravida Serum POSTN and PAPPA as the Potential Biomarkers for Fetal Congenital Heart Disease Based on Quantitative and Qualitative Proteomics

2021 ◽  
Author(s):  
Yi Xia ◽  
Lin Cheng ◽  
Jie Duan ◽  
Jianhong Ma ◽  
Juan Liu ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Amniotic Fluid ◽  
Congenital Heart ◽  
Diagnostic Model ◽  
Protein Biomarkers ◽  
Data Independent Acquisition ◽  
Parallel Reaction Monitoring ◽  
Auc Value ◽  
Potential Biomarkers

Abstract Background: Fetal congenital heart disease is the most common congenital defect worldwide. It has some missed diagnoses and a lack of disease biomarkers. We aim to seek objective biomarkers for noninvasive prenatal diagnosis of fetal congenital heart disease to reduce the missed diagnosis and explore its mechanism,Methods: This study used data-independent acquisition and parallel reaction monitoring to explore potential protein biomarkers that co-exist in gravida serum and fetal amniotic fluid. Moreover, logistic regression and ROC curve to establish the diagnostic model of fetal congenital heart disease potential biomarkers and molecular biology experiments were performed to validate proteomics results and explore the mechanism. Results: Proteomics and bioinformatics results show that 12 proteins co-exist in gravida serum and amniotic fluid. We identified POSTN and PAPPA in GS as candidate biomarkers and established the diagnostic model with a sensitivity of 100%, a specificity of 95% and the AUC value of 0.968 to diagnose congenital heart disease. In addition, the results of ELISA, IHC, and RT-PCR were consistent with those of proteomics. Moreover, POSTN may involve in fetal congenital heart disease through the TGF-beta signaling pathway. Conclusion: It is the first time to find that POSTN and PAPPA in GS are related to fetal congenital heart disease, contributing to developing a novel noninvasive prenatal method to diagnose fetal congenital heart disease and reduce congenital disabilities.

scholarly journals Potential biomarkers and targets in reversibility of pulmonary arterial hypertension secondary to congenital heart disease: an explorative study

2018 ◽  
Vol 8 (2) ◽  
pp. 204589321875598 ◽  
Author(s):  
Li Huang ◽  
Li Li ◽  
Enci Hu ◽  
Guo Chen ◽  
Xianmin Meng ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Arterial Hypertension ◽  
Cathepsin D ◽  
Lung Biopsy ◽  
Congenital Heart ◽  
Filamin A ◽  
Caveolin 1 ◽  
Pulmonary Arterial ◽  
Potential Biomarkers

Whether pulmonary arterial hypertension (PAH) is reversible in congenital heart disease (CHD) is important for the operability of CHD. However, little is known about that. Our research was aimed at exploring novel biomarkers and targets in the reversibility of CHD-PAH. CHD-PAH patients diagnosed with right heart catheterization (RHC) were enrolled (n = 14). Lung biopsy was performed during the repair surgery. After one year follow-up, mean pulmonary arterial pressures (mPAP) were evaluated by RHC to determine the diagnosis of reversible (mPAP < 25 mmHg, n = 10) and irreversible (mPAP ≥ 25 mmHg, n = 4) PAH. Harvested normal lung tissues (n = 6) were included as the control group. Pulmonary arteriole lesions were identified by pathological grading in tissue staining. iTRAQ-labelled mass-spectrometry analysis followed by immunohistochemistry and western blot was used to explore the most meaningful differential proteins. For enrolled patients, the histopathological grading of pulmonary vascular lesions in reversible CHD-PAH patients was all at grades 0–II while grades III–IV were shown only in irreversible CHD-PAH patients. Proteomic analysis identified 85 upregulated and 75 downregulated proteins, including cytoskeletal proteins and collagen chains, mainly involved in cell adhesion, extracellular matrix, cytoskeleton, immune response, and complement pathways. Among them, caveolin-1, filamin A expression, and cathepsin D combined with macrophagocytes counts were significantly increased; glutathione S-transferase mu1 (GSTM1) expression was significantly decreased in the irreversible CHD-PAH group (all P < 0.05). Caveolin-1, filamin A, and cathepsin D expression showed a positive relation and GSTM1 showed a negative relation with pathological grading. Upregulated caveolin-1, filamin A, and cathepsin D combined with increased macrophagocytes and downregulated GSTM1 may be potential biomarkers and targets in the irreversibility CHD-PAH, and which may be useful in evaluating the operability and understanding the irreversibility of CHD-PAH. Expression of these pathological biomarkers combined with pathological changes in lung biopsy may have great value in predicting the irreversibility of PAH.

scholarly journals Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics

2021 ◽  
Vol 8 ◽  
Author(s):  
Yahong Li ◽  
Yun Sun ◽  
Lan Yang ◽  
Mingtao Huang ◽  
Xiaojuan Zhang ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Uric Acid ◽  
Heart Disease ◽  
Amniotic Fluid ◽  
Congenital Heart ◽  
Partial Least Square ◽  
Least Square ◽  
Flight Mass Spectrometry ◽  
Validation Set ◽  
Control Samples

Congenital heart disease (CHD) is the most common birth defect. The prenatal diagnosis of fetal CHD is completely dependent on ultrasound testing, but only ~40% of CHD can be detected. The purpose of this study is to find good biomarkers in amniotic fluid (AF) to detect CHD in the second trimester, so as to better manage this group of people and reduce the harm of CHD to the fetus. Metabolites analysis were performed in two separate sets. The discovery set consisted of 18 CHD fetal maternal AF samples and 35 control samples, and the validation set consisted of 53 CHD fetal maternal AF samples and 114 control samples. Untargeted metabolite profiles were analyzed by gas chromatography/time-of-flight-mass spectrometry (GC-TOF/MS). Orthogonal partial least square discrimination analysis (OPLS-DA) demonstrated that CHD and control samples had significantly different metabolic profiles. Two metabolites, uric acid and proline, were significantly elevated in CHD and verified in two data sets. Uric acid was associated with CHD [odds ratio (OR): 7.69 (95% CI: 1.18–50.13) in the discovery set and 3.24 (95% CI:1.62–6.48) in the validation set]. Additionally, uric acid showed moderate predictive power; the area under curve (AUC) was 0.890 in the discovery set and 0.741 in the validation set. The sensitivity and specificity of uric acid to detect CHD was, respectively, 94.4 and 74.3% in the discovery set and 67.9 and 71.9% in the validation set. The identification of uric acid as a biomarker for CHD has the potential to stimulate research on the pathological mechanism of CHD and the development of a diagnostic test for clinical applications.

Sign in / Sign up

Export Citation Format

Share Document